Your search history is turned on.
Date: April 18, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update WARMINSTER, Pa., April 18, 2024 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 fin...
Date: April 4, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 _______________________________ Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter)...
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna WARMINSTER, Pa., April 04, 2024 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today issued the following statemen...
Date: March 8, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Arbutus to Participate in Two Upcoming Investor Conferences WARMINSTER, Pa., March 08, 2024 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one mee...
Date: March 6, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
2023 10-K (filed)-2024-03-05-17-01 CERTIFICATION PURSUANT TO RULE 13a-14 AND 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David C. Hastings, Chief Financial Officer of Arbutus Biopharma Corporation, certify that: 1. I have reviewed this Annual Report on Form 10-K of Arbutus Biopharm...
2023 10-K (filed)-2024-03-05-17-01 CERTIFICATION PURSUANT TO RULE 13a-14 AND 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael J. McElhaugh, Interim President and Chief Executive Officer of Arbutus Biopharma Corporation, certify that: 1. I have reviewed this Annual Report on Form...
2023 10-K (filed)-2024-03-05-17-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...
2023 10-K (filed)-2024-03-05-17-01 Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations Overview Arbutus Biopharma Corporation (Arbutus, the Company, we, us, and our) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with d...
Date: March 6, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, HASTINGS, David C., an officer of the reporting issuer noted below have examined this Form 13- 502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reaso...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...